Display Settings:


Send to:

Choose Destination
Haematologica. 2011 Mar;96(3):464-7. doi: 10.3324/haematol.2010.033514. Epub 2010 Dec 6.

Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.

Author information

  • 1Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research. 3-8-31 Ariake, Koto, Tokyo 135-8550, Japan. kentakeuchi-tky@umin.net


ALK-positive large B-cell lymphoma is a rare subtype of lymphoma, and most cases follow an aggressive clinical course with a poor prognosis. We examined an ALK-positive large B-cell lymphoma case showing an anti-ALK immunohistochemistry pattern distinct from those of 2 known ALK fusions, CLTC-ALK and NPM-ALK, for the presence of a novel ALK fusion; this led to the identification of SQSTM1-ALK. SQSTM1 is an ubiquitin binding protein that is associated with oxidative stress, cell signaling, and autophagy. We showed transforming activities of SQSTM1-ALK with a focus formation assay and an in vivo tumorigenicity assay using 3T3 fibroblasts infected with a recombinant retrovirus encoding SQSTM1-ALK. ALK-inhibitor therapies are promising for treating ALK-positive large B-cell lymphoma, especially for refractory cases. SQSTM1-ALK may be a rare fusion, but our data provide novel biological insights and serve as a key for the accurate diagnosis of this rare lymphoma.

[PubMed - indexed for MEDLINE]
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1.
Figure 2.

Publication Types, MeSH Terms, Substances, Supplementary Concepts, Secondary Source ID

Publication Types

MeSH Terms


Supplementary Concepts

Secondary Source ID

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk